AbbVie's etentamig meets Phase 3 endpoints in multiple myeloma trial

September 3, 2026 9:15 AM

AbbVie (NYSE: ABBV) reported that its investigational drug etentamig met dual primary endpoints in the Phase 3 CERVINO trial, showing ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found